An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience

Trial Profile

An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Biomarker; Pharmacodynamics
  • Acronyms FAIR
  • Sponsors AbbVie
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jul 2015 Last checked against ClinicalTrials.gov record.
    • 28 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top